domingo, 25 de mayo de 2014

Distinguishing Nontuberculous Mycobacteria from Multidrug-Resistant Mycobacterium tuberculosis, China - Volume 20, Number 6—June 2014 - Emerging Infectious Disease journal - CDC

Distinguishing Nontuberculous Mycobacteria from Multidrug-Resistant Mycobacterium tuberculosis, China - Volume 20, Number 6—June 2014 - Emerging Infectious Disease journal - CDC

link to Volume 20, Number 6—June 2014

Volume 20, Number 6—June 2014


Distinguishing Nontuberculous Mycobacteria from Multidrug-Resistant Mycobacterium tuberculosis, China

To the Editor: Mycobacteria are commonly characterized by positive acid-fast staining. Most mycobacterial species belong to the nontuberculous mycobacteria (NTM), excluding species in the Mycobacterium tuberculosis complex and M. leprae. Both M. tuberculosis and NTM can induce pulmonary infection with similar symptoms and pulmonary radiographic findings (1). These similarities have led to difficulty in distinguishing these infections clinically.
As in many developing countries, the acid-fast stain is the only bacteriologic basis for diagnosing tuberculosis (TB) in primary health care institutions in China, where facilities are limited for M. tuberculosis culture, strain identification, and drug resistance detection. Thus, NTM is easily misdiagnosed as M. tuberculosis, and multidrug-resistant (MDR) TB is unable to be accurately identified. Patients with misdiagnosed TB usually are treated with the standard anti-TB regimens recommended by the Chinese government (i.e., 2HRZE/4HR [2 months of isoniazid (INH), rifampin (RIF), pyrazinmid, and ethambutol, followed by 4 months of INH and RIF 1 time daily] and 2H3R3Z3E3/4H3R3 [2 months of INH, RIF, pyrazinamide, and ethambutol followed by 4 months of INH and RIF 3 times weekly]) (2), which often results in treatment failures. Misdiagnosis is a key hurdle for effective prevention and treatment of TB (35). To evaluate the effect of misdiagnosis on TB prevention, we determined the proportion of patients with MDR TB and NTM infection in primary health care institutions in Zhejiang Province, China. Our findings would be useful for improving TB prevention and treatment.
During 2011–2012, sputum samples from 13,882 patients suspected of having TB in 8 counties in Zhejiang Province were used to culture mycobacteria. Each sample was seeded onto 2 pieces of Löwenstein-Jensen medium. A total of 1,410 samples grew mycobacteria confirmed as acid-fast bacilli by using Ziehl-Neelsen staining. The 1,410 samples were further identified by using the Mycobacteria Identification Array Kit (CapitalBio, Beijing, China). The kit contains 17 types of bacilli-specific 16S rRNA probes (i.e., M. tuberculosis complex, M. aviumM. intracellulareM. gilvumM. xenopiM. smegmatisM. aurumM. terraeM. gordonaeM. chelonae/abscessusM. phleiM. scrofulaceumM. fortuitumM. szulgaiM. ulceransM. marinum, and M. kansasii). With this method, M. tuberculosis and NTM can be distinguished, and the species of NTM can be identified (68). Of 1,410 positive strains, we identified 1,332 (94.5%) as M. tuberculosis and 78 (5.5%) as NTM. NTM strains were further identified as follows: M. intracellulare, 39 isolates; M. chelonae/abscessus, 12 isolates, M. kansasii, 13 isolates; M. avium, 3 isolates; M. fortuitum, 4 isolates; and M. scrofulaceum and M. szulgai, 1 isolate each. For 5 isolates, strain could not be classified.
We detected drug resistance of 1,332 M. tuberculosis strains using a Tuberculosis Drug Resistance Detection Array Kit (CapitalBio) (9). The mutant points for RIF resistance were identified as follows: rpoB/C531G, C531T, CG531AC, A526C, A526G, A526T, C526A, C526G, C526T, T533C, A516G, A516T, G516T, T511C, T511G, C513A, A513T, and C522T (Table). Moreover, the kit contained 5 mutant points for INH resistance, including katG (G315A, G315C, G315T, and C315) and inhA (C-15T) (Table). Of 1,332 M. tuberculosis strains, we identified 1,115 (83.7%) RIF/INH-sensitive strains, 88 (6.6%) MDR TB strains, 83 (6.2%) INH-resistant strains, and 47 (3.5%) RIF-resistant strains. Of the 1,410 positive strains, 88 (6.2%) were MDR M. tuberculosis strains.
The epidemiology of TB in Zhejiang Province reflects the situation in China and some developing countries (10). The clinical diagnosis and treatment of >80% TB cases in China is performed mainly by primary health care institutions. However, almost 80% of these medical institutions do not have the capability to culture M. tuberculosis, detect drug resistance, and identify strains (7). Of 1,410 strains obtained from the patients in 8 counties of Zhejiang Province, 218 (15.5%) were MDR TB, INH resistant, and RIF resistant. These affected patients could not be effectively treated with the national standard regimens. Specifically, 88 patients with MDR TB would be at risk for extensively drug-resistant TB, and 83 patients with INH-resistant TB and 47 with RIF-resistant TB would be at risk for MDR TB. In addition, we identified 78 (5.5%) NTM strains. With the acid-fast stain, these illnesses would be misidentified as TB and, in most instances, also would be reported as treatment failures. Clearly, accurate diagnosis provided by the technologies used in this study for distinguishing NTM and M. tuberculosisMycobacterium strain identification, and drug-resistance detection would increase the cure rate and effectively prevent TB epidemics.
For INH resistance, katG315 was a main mutant point of the M. tuberculosis strain; 140 (81.4%) of the 172 INH-resistant mutations were related to katG315. For RIF resistance, rpoB531 was a main mutant point; 84 (60.0%) of 140 RIF-resistant mutations were associated with rpoB531. Therefore, in future studies, more attention should be paid to the molecular epidemiology ofkatG315 and rpoB531.
In conclusion, using the techniques for M. tuberculosis culture, Mycobacterium strain identification, and drug-resistance detection is necessary. It should be urgently pursued for accurate TB diagnosis in primary health care institutions in China to improve the prevention, treatment, and control of TB.
Kaijin Xu, Sheng Bi, Zhongkang Ji, Haiyang Hu, Feisu Hu, Beiwen Zheng, Bing Wang, Jingjing Ren, Shigui Yang, Min Deng, Ping Chen, Bing Ruan, Jifang Sheng, and Lanjuan LiComments to Author 
Author affiliations: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (K. Xu, S. Bi, Z. Ji, H. Hu, F. Hu, B. Zheng, B. Wang, J. Ren, S. Yang, M. Deng, P. Chen, B. Ruan, J. Sheng, L. Li)Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou (K. Xu, L. Li)


This study was funded by the National Scientific and Technological Major Project of China (grant no. 2009ZX10004-901,2011ZX10004-901), State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, and the National Natural Science Foundation of China (grant no.81070285).


  1. McGrath EEMcCabe JAnderson PBGuidelines on the diagnosis and treatment of pulmonary non-tuberculous mycobacteria infection. Int J Clin Pract2008;62:194755DOIExternal Web Site IconPubMedExternal Web Site Icon
  2. Chinese Center for Disease Control and Prevention, Ministry of Health of the People’s Republic of China. China TB control programme implementation guide (2008) [cited 2014 Apr 16]. Web Site Icon
  3. Zhao YXu SWang LChin DPWang SJiang GNational survey of drug-resistant tuberculosis in China. N Engl J Med2012;366:216170DOIExternal Web Site IconPubMedExternal Web Site Icon
  4. Hofmann-Thiel STuraev LAlnour TDrath LMüllerova MHoffmann HMulti-centre evaluation of the speed-oligo mycobacteria assay for differentiation of Mycobacteriumspp. in clinical isolates. BMC Infect Dis2011;11:353DOIExternal Web Site IconPubMedExternal Web Site Icon
  5. Maiga MSiddiqui SDiallo SDiarra BTraoré BShea YRFailure to recognize nontuberculous mycobacteria leads to misdiagnosis of chronic pulmonary tuberculosis.PLoS ONE2012;7:e36902DOIExternal Web Site IconPubMedExternal Web Site Icon
  6. Zhu LJiang GWang SWang CLi QYu HBiochip system for rapid and accurate identification of mycobacterial species from isolates and sputum. J Clin Microbiol.2010;48:365460DOIExternal Web Site IconPubMedExternal Web Site Icon
  7. Pang YZhou YWang STan YYue JZhao BRapid molecular identification of mycobacterial species in positive culture isolates using the biochip test. Int J Tuberc Lung Dis2011;15:16805DOIExternal Web Site IconPubMedExternal Web Site Icon
  8. Liu JYue JYan ZHan MHan ZJin LPerformance assessment of the CapitalBiol mycobacterium identification array system for identification of mycobacteria. J Clin Microbiol2012;50:7680DOIExternal Web Site IconPubMedExternal Web Site Icon
  9. Guo YZhou YWang CZhu LWang SLi QRapid and accurate determination of MDR-TB in M. tuberculosis isolates and clinical sputum using a biochip system. Int J Tuberc Lung Dis2009;13:91420 .PubMedExternal Web Site Icon
  10. The Office of the Fifth National TB Epidemiological Survey, Technical Guidance Group of the Fifth National TB Epidemiological Survey. The Fifth National Tuberculosis Epidemiological Survey in 2010. Chinese Journal of Antituberculosis. 2012;34:485–508 [cited 2014 Apr 16]. Web Site Icon


Suggested citation for this article: Xu K, Bi S, Ji Z, Hu H, Hu F, Zheng B, et al. Distinguishing nontuberculous mycobacteria from multidrug-resistant Mycobacterium tuberculosis, China [letter]. Emerg Infect Dis [Internet]. 2014 Jun [date cited]. Web Site Icon
DOI: 10.3201/eid2006.130700

No hay comentarios:

Publicar un comentario